Finding the right book can make a big difference, especially when you’re just starting out or trying to get better. We’ve ...

Bitterly cold arctic air has blanketed parts of the United States over the last week, with some areas getting snow and subzero temperatures. Along with the cold weather comes a natural event called ...

Severe cold temperatures hitting much of the country this week could branch out − literally. As people brace for the winter weather, some social media posts in recent days have warned of the chance ...

John Seiler was strolling across Virginia Tech’s campus with his students Thursday morning when something stopped them in their tracks: a sweet cherry tree with an unusual jagged scar running along ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

It was one Christmas visitor that didn’t overstay its welcome. A Burmese python that had been spotted in a Miami-Dade neighborhood was removed just days before Christmas after a resident out for a ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.